TG/HDLC值与ACS患者经皮冠状动脉介入治疗术后院内主要不良心血管事件的相关性

目的研究血清TG/HDLC值与急性冠状动脉综合征(ACS)患者经皮冠状动脉介入治疗(PCI)术后院内主要不良血管事件(MACE)的相关性。方法选取2014年1月至2015年1月洛阳市中心医院接受PCI治疗的患者214例,应用多因素Logistic回归分析TG/HDLC是否可作为ACS患者发生院内主要不良血管事件的独立危险因素,根据TG/HDLC值分为高TG/HDLC值组(66例)、中TG/HDLC值组(74例)、低TG/HDLC值组(74例),对三组患者院内发生主要不良心血管事件的风险进行比较。结果多因素Logistic回归模型中,通过校正年龄、性别、吸烟史、高血压病史、糖尿病史和冠状动脉狭窄程度,Log TG/HDLC值是ACS患者院内主要不良血管事件的独立危险因素(OR=6.90,95%CI为1.90~25.06,P=0.003),高TG/HDLC值组发生不良心血管事件风险是低TG/HDLC值组的3.27倍。结论 TG/HDLC值对ACS患者PCI术后院内主要不良心血管事件的发生具有重要的预测价值。     

Lp-PLA2、F-ABP、PLR对急性心肌梗死患者院内主要不良心脏事件的影响

目的 探讨脂蛋白相关磷脂酶A2(Lp-PLA2)、心脏型脂肪酸结合蛋白（F-ABP）、血小板/淋巴细胞比值（PLR）对急性心肌梗死（AMI）患者院内主要不良心脏事件（MACE）的影响。方法 回顾性分析2015年1月至2020年9月明确诊断为AMI的159例患者的临床资料,根据超声心动图ST段是否抬高分为急性ST段抬高型心肌梗死（S组,n=81）与急性非ST段抬高型心肌梗死（NS组,n=78）。随机抽取同期因胸痛、胸闷入院的非AMI患者80例作为对照组（C组,n=85）。比较3组Lp-PLA2、F-ABP、PLR水平及MACE发生率。采用单因素分析筛选出与院内MACE存在关联的变量,采用多变量logistic回归法构建MACE预测模型。采用Pearson相关分析和ROC曲线分析3项指标的预后效能。结果 S组、NS组男性、吸烟、WBC、NT-proBNP、cTnI、D-dimer、Fg、Lp-PLA2、F-ABP、PLR、Gensini评分高于C组,LVEF、纤维帽厚度低于C组（P<0.05）;S组WBC、LVDD、NT-proBNP、cTnI、D-dimer、Fg、Lp-PLA2、...     

经皮冠状动脉介入治疗术后患者口服低剂量与高剂量阿司匹林对不良心脑血管事件的影响

目的 通过比较我国经皮冠状动脉介入治疗（percutaneous coronary intervention,PCI）术后患者采用低剂量阿司匹林与高剂量阿司匹林对预防不良心脑血管事件的有效性和安全性,以及检测服用不同剂量阿司匹林后血浆中血栓烷素B2（thromboxane B2,TXB2）和P选择素的水平,探讨PCI后口服低剂量阿司匹林的策略是否适合我国人群,为我国PCI术后患者口服阿司匹林的合理剂量提供依据.方法 于2011年5月至2012年12月,在长海医院心血管病科连续入选PCI术后患者400例,随机分为低剂量阿司匹林组（PCI术后阿司匹林100 mg/d）和高剂量阿司匹林组（PCI术后阿司匹林300mg/d,服用3个月后改为100 mg/d）,对入选患者分别在PCI术后住院期间,以及术后1个月、3个月、6个月及12个月时进行随访,主要终点是主要不良心脑血管事件.结果 在入选的400例患者中失访11例,其余389例中包括低剂量阿司匹林组198例,高剂量阿司匹林组191例.随访3个月时共有7例患者发生心脑血管事件,其中低剂量阿司匹林组3例（1.5％）,高剂量阿司匹林组4例（2.1％）;低剂量阿司匹林组、高剂量阿司匹林组的次要出血事件发生率分别是7例（3.5％）和8例（4.2％）,主要出血事件发生率均为2例（1.0％）,两组间心脑血管事件以及出血事件发生率比较,差异均无统计学意义（P＞0.05）.12个月时共有11例发生心脑血管事件,其中低剂量阿司匹林组6例（3.0％）,高剂量阿司匹林组5例（2.6％）;低剂量阿司匹林组、高剂量阿司匹林组的次要出血事件发生率分别是10例（5.1％）、11例（5.8％）,主要出血事件发生率分别是3例（1.5％）和2例（1.0％）,两组间心脑血管事件以及出血事件发生率比较,差异均无统计学意义（P＞0.05）.阿司匹林上消化道症状（反酸、嗳气、上腹不适）在低剂量组、高剂量组的发生率分别是4例（2.0％）、12例（6.3％）（P＜0.05）,差异有统计学意义;比较两组间血浆中TXB2、P选择素水平,均无统计学差异,P＞ 0.05.结论 PCI术后服用低剂量阿司匹林是有效和安全的;低剂量阿司匹林组上消化道症状的发生率低于高剂量组.     

Ⅱ期和Ⅲ期心脏康复治疗对急性冠状动脉综合征患者经皮冠状动脉介入治疗后预后的影响

目的 探讨Ⅱ期和Ⅲ期心脏康复治疗对急性冠状动脉综合征(ACS)患者经皮冠状动脉介入治疗(PCI)术后生活质量、心功能和远期预后的影响.方法 采用随机数字表法将150例行PCI的ACS患者分为试验组和对照组,每组各75例,对照组患者PCI后常规进行一般情况评估、健康教育、心理干预、运动干预及规范冠心病用药;试验组患者在以...     

血清总胆红素水平与冠状动脉介入围手术期心血管事件的关系

目的探讨血清总胆红素水平与经皮冠状动脉介入治疗(PCI)治疗不稳定型心绞痛围手术期发生主要不良心血管事件(MACE)的相关性。方法分析2012年1月至2015年3月在我院行PCI术的1113例不稳定型心绞痛患者,统计其血清总胆红素等生化指标、临床资料特点、PCI手术资料,记录围手术期MACE的发生情况,将患者按有无不良心血管事件发生分为MACE组和非MACE组。结果 MACE组血清总胆红素水平较非MACE组明显降低(9.32±2.79μmpl/L比11.97±5.20μmpl/L;P0.01),以COX回归进行多因素分析显示血清总胆红素水平升高为不稳定型心绞痛患者行PCI术围手术期MACE发生的独立保护因子(RR=0.917,95%CI为0.867~0.970,P0.01)。结论高血清总胆红素是PCI术治疗不稳定型心绞痛围手术期MACE发生的独立保护因素。     

经皮冠状动脉介入治疗术后炎症指标对急性冠脉综合征患者预后影响

目的 前瞻性观察接受经皮冠状动脉介入治疗（percutaneous coronary intervention,PCI）的急性冠脉综合征患者PCI术后中性粒细胞/淋巴细胞比值（neutrophil to lymphocyte ratio,NLR）、血小板/淋巴细胞比值（platelet to lymphocyte ratio,PLR）、C反应蛋白（ C-reactive protein?,CRP）、降钙素原（procalcitonin,PCT）、白细胞介素-6（interleukin-6,IL-6）等炎症指标水平对近期预后的影响。方法　214例急性冠脉综合征患者行PCI治疗手术后次日清晨,抽取外周肘静脉血行全血细胞测定（计算NLR和PLR）和 CRP、PCT、IL-6等炎症因子检测。应用二分类Logistic 多因素回归模型分析急性冠脉综合征PCI术后主要心脏不良事件 (?major adverse cardiac events,MACE)?发生的影响因素;ROC曲线评估上述炎症指标对急性冠脉综合征患者PCI术后MACE发生的预测价值。结果　214例急性冠脉综合征患者,平均随访12月（中位数）,共累计33例患者（15.4%）出现MACE事件。应用二分类Logistic 多因素回归模型分析,发现NLR[（odds ratio,OR值）2.98,P<0.001]和急性冠脉综合征类型（OR=0.29,P=0.048）是PCI术后MACE发生的独立影响因素。ROC曲线评估分析发现,NLR、PLR、CRP、PCT、IL-6均有预测PCI术后MACE发生的价值（P<0.01）,但是NLR预测MACE发生的ROC曲线下面积最大（0.898）,NLR预测PCI术后MACE事件发生最佳切点为3.94。结论 PCI术后NLR、PLR、CRP、PCT、IL-6等炎症指标均具有预测PCI术后MACE发生的价值,而NLR的预测价值最高。PCI术后过高的NLR和急性ST段抬高型心肌梗死是急性冠脉综合症患者PCI术后MACE发生的独立影响因素。     

老年经皮冠状动脉介入患者血糖水平与心肌灌注及不良心脏事件的关系

目的探讨老年经皮冠状动脉介入手术(PCI)患者血糖水平与心肌灌注及不良心脏事件的关系。方法接受PCI再灌注治疗的急性ST段抬高型心肌梗死(STEMI)患者394例,根据患者的血糖水平分成对照组(血糖水平<7.0 mmol/L)136例及血糖上升组(血糖水平7.0~11.1 mmol/L)148例、高血糖组(血糖水平>11.1 mmol/L)110例。对比各组PCI术后的心肌灌注和心功能指标,随访6个月,记录患者的不良心脏事件发生情况,Logistic回归分析评价影响PCI术后不良心脏事件的危险因素。结果血糖上升组与高血糖组肌酸激酶同工酶(CK-MB)峰值明显高于对照组,左室射血分数(LVEF)水平、ST段回落较好及心肌灌注的血流分级(TMPG)2~3级的比例明显低于对照组,高血糖组CK-MB峰值明显高于血糖上升组,LVEF水平明显低于血糖上升组(均P<0.05)。394例患者PCI术后发生不良心脏事件者62例(15.74%)。PCI术后发生不良心脏事件者存在应激性高血糖(SHG)、TMPG 0~1级、吸烟及泵衰竭≥Ⅱ级的比例均分别明显高于未发生不良心脏事件者(均P<0.05),且Logistic回归分析显示,上述4个指标均是影响PCI术后不良心脏事件的危险因素。结论老年PCI患者的血糖水平与其心肌灌注以及不良心脏事件之间均存在紧密联系,存在SHG、TMPG 0~1级、吸烟以及泵衰竭≥Ⅱ级会增加PCI术后不良心脏事件发生风险。     

血清sST2、Lp-PLA2与冠心病经皮冠状动脉介入术后MACE事件发生的关系

目的探讨血清可溶性生长刺激表达基因蛋白2(soluble growth-stimulated gene protein 2,sST2)、脂蛋白相关磷脂酶A2(lipoprotein-associated phospholipase A2,Lp-PLA2)与冠心病经皮冠状动脉介入术(PCI)后不良心血管事件(MACE)发生的关系。方法选取徐州市中心医院2015年1月至2018年2月实施PCI手术治疗,且至少接受12个月随访观察的冠心病患者138例作为研究对象,依据患者随访12个月内是否出现MACE事件分为MACE组39例、非MACE组99例,对比两组患者血清sST2、Lp-PLA2水平及一般资料,采用非条件Logistic回归分析法分析血清sST2、Lp-PLA2水平与MACE事件的关系。结果 MACE组、非MACE组患者的年龄、性别、吸烟、饮酒、体质量指数(BMI)、合并疾病(高血压、血脂异常)、PCI术后用药比较,差异均无统计学意义(P> 0.05);MACE组合并糖尿病、急性心肌梗死患者占比均高于非MACE组患者,差异均具有统计学意义(χ~2=4.943、5.633,P <0.05);MACE组患者的血清sST2、Lp-PLA2水平均高于非MACE组患者,差异均具有统计学意义(t=13.342、3.326,P <0.05);经非条件Logistic回归分析,冠心病患者合并糖尿病、急性心肌梗死、血清sST2、Lp-PLA2水平升高会增大PCI术后发生MACE事件的风险(Waldχ~2=4.310、4.901、5.449、5.805、5.648,P <0.05)。结论血清sST2、Lp-PLA2水平升高是冠心病患者PCI术后并发MACE事件的危险因素。     

糖化血清白蛋白水平与急性冠状动脉综合征患者经皮冠状动脉介入治疗术预后的相关性研究

目的:本研究的旨在研究经皮冠状动脉介入治疗(PCI)术后急性冠状动脉综合征(ACS)患者的糖化血清白蛋白(GA)水平与不良心血管事件关系,探究联合传统危险因素及GA预测PCI术后ACS患者预后的效果.方法:回顾性分析2018年6月至2019年8月,因ACS在我院住院期间接受PCI治疗的,年龄≥18岁患者,采用Cox风险...     

老年急性心肌梗死患者营养状态与经皮冠状动脉介入术后主要不良心血管事件的关系

目的 探讨老年急性心肌梗死（心梗）患者营养状态与经皮冠状动脉介入术（PCI）后主要不良心血管事件（MACE）的相关性,分析控制营养状态评分（CONUT）预测老年急性心梗患者PCI后发生MACE的价值。方法 选择2016年1月至2020年1月于联勤保障部队第900医院收治的250例老年急性心梗患者,采用COUNT法评估患者营养状态,收集临床资料,术后随访12个月,根据术后是否发生MACE将患者分为MACE组（61例）和NMACE组（189例）。Logistic回归分析影响老年急性心梗患者PCI后发生MACE的因素。受试者工作特征曲线（ROC）分析COUNT评分对老年急性心梗患者PCI后发生MACE的预测价值。结果 MACE组患者COUNT评分高于NMACE组（P<0.05）,白蛋白（ALB）、前白蛋白（PA）、总淋巴细胞计数低于NMACE组（P<0.05）。PCI后MACE发生率随着营养不良程度加重而增高（P<0.05）。术前高Gensini评分（OR=1.756,95%CI:1.697～1.877）、低左室射血分数（LVEF）(OR=1.701,95%CI:1.668...     

Symptoms of Disturbed Sleep Predict Major Adverse Cardiac Events After Percutaneous Coronary Intervention

Background

Disturbed sleep is associated with atherosclerosis in native coronary arteries and may be associated with adverse cardiac events after percutaneous coronary intervention (PCI). We sought to determine the association between symptoms of disturbed sleep and adverse cardiovascular events after PCI.

Methods

Outpatients who were stable after successful PCI were assessed for symptoms of disturbed sleep with 10 true/false questions. Follow-up was performed at least 4 years after PCI. The primary outcome was a composite of death, myocardial infarction (MI), and repeated revascularization.

Results

Three hundred eighty-eight patients (mean age, 66 ± 11 years) reported on average 3.1 ± 2.1 sleep disturbance symptoms. Follow-up was performed on average 4.4 years after the incident PCI. The primary outcome occurred in 25% of patients. An association was seen between the number of sleep disturbance symptoms and the occurrence of the primary end point. Patients with zero symptoms had a 4-year event rate of 12% compared with a 67% event rate for those with 9 symptoms. On multivariable analysis, sleep symptoms, diabetes mellitus, and the number of diseased coronary vessels were independently associated with the primary end point. Each additional sleep symptom was associated with a hazard ratio (HR) of 1.2 (P = 0.001). The results were driven primarily by the association between symptoms of disturbed sleep and the need for repeated revascularization (repeated PCI HR, 1.9; P = 0.003; coronary artery bypass grafting (CABG) HR, 1.5; P = 0.001).

Conclusions

Symptoms of disturbed sleep were associated with increased risk of long-term adverse cardiovascular outcomes after successful PCI.     

Major Adverse Cardiac Events at Long-Term Follow-Up in Patients Treated With Single versus Multiple Stents during Single-Vessel Percutaneous Coronary Intervention

Background: Although insertion of multiple stents into a single coronary vessel during single-vessel percutaneous coronary intervention (PCI) is common, there are no data on long-term occurrence of major adverse cardiac events (MACE) in patients treated with multiple stents versus a single stent.
Methods: The incidence of MACE (death, myocardial infarction, or target vessel revascularization) during long-term follow-up was investigated in 634 patients who underwent single-vessel PCI. Of the 634 patients, 319 (50%) had a single stent, and 315 (50%) had multiple stents inserted. Stepwise Cox regression analyses were performed to identify significant independent prognostic factors for MACE.
Results: At 47-month follow-up, MACE occurred in 61 of 319 patients (19%) who had a single stent versus in 57 of 315 patients (18%) who had multiple stents (P not significant). Significant independent predictors of MACE were use of vein grafts (hazard ratio = 1.94; 95% CI, 1.24–3.03; P = 0.0038) and use of drug-eluting stents (hazard ratio = 0.49; 95% CI, 0.34–0.72; P = 0.0002).
Conclusions: At long-term follow-up of single-vessel PCI, the incidence of MACE was similar in patients with multiple or single stents inserted even after controlling for the length of stents.     

Serum Apelin Level Predicts the Major Adverse Cardiac Events in Patients With ST Elevation Myocardial Infarction Receiving Percutaneous Coronary Intervention

The cardiovascular profile of the apelin makes it a promising therapeutic target for heart failure and ischemic heart disease. However, it remains unknown whether apelin affect the clinical outcome of patients with ST elevation myocardial infarction (STEMI) and received percutaneous coronary intervention (PCI).We enrolled a total of 120 patients with acute STEMI who underwent primary PCI. Serum apelin was detected. After PCI procedure, all patients were followed for 12 months. The follow-up end-point was occurrence of major adverse cardiovascular event (MACE).Lower serum apelin levels (<0.54 ng/mL) was significantly associated with higher serum low density lipoprotein-cholesterol level, higher peak creatine kinase MB fraction (CK-MB) and peak troponin-I (TNI) levels, the number of obstructed vessels, and need for inotropic support. The incidence of MACE was significantly higher in the low apelin group (23 patients out of 67) than in the high apelin group (10 patients out of 75, P < 0.001). Kaplan–Meier analysis revealed that the MACE-free rate was significantly lower in the patients with low apelin than those with high apelin (P < 0.001, log rank test). The multivariate Cox proportional hazard analysis adjusted with the clinical and angiographic characteristic reveals that the serum low apelin is a predictor for MACE incidence (hazard ratio = 2.36, 95% confidence interval: 1.83–3.87, P = 0.004).The finding of this study suggests that the serum apelin may be used as a marker to predict the MACE after PCI in patients with STEMI.     

冠心病患者冠状动脉介入治疗前后血浆高敏C反应蛋白水平的变化及其与主要不良心血管事件的关系

目的通过比较冠心病患者药物洗脱支架植入前后血浆高敏C反应蛋白(hs-CRP)的变化,判断机体介入前后炎症状况,并随访不良心血管事件,分析炎症因子与主要不良心血管事件的关系。方法入选从2013年10月1日至2014年6月17日在北京大学第一医院心血管内科就诊并行冠状动脉介入治疗的冠心病患者,签署知情同意书,收集其临床资料和介入手术情况,采集其介入治疗前、介入治疗后1天及30天的血样标本,测定hs-CRP浓度,比较介入治疗前后hs-CRP的变化,介入治疗1年后电话随访所有入选患者,收集主要不良心血管事件的发生率。结果共入选资料完整的冠心病患者84例。介入治疗1天后血浆hs-CRP水平与术前无显著差异(10.00±24.81 mg/L比7.52±17.90 mg/L,P=0.409),介入治疗30天后血浆hs-CRP水平较术前明显降低(2.80±4.66mg/L比7.52±17.90 mg/L,P0.001),较术后1天亦显著降低(P0.001);介入治疗后1年内有16人发生主要不良心血管事件,有事件的患者术前hs-CRP水平高于无事件患者(10.38±19.40 mg/L比6.84±17.61 mg/L,P=0.018),但术后1天hs-CRP水平无显著差异(12.91±27.76 mg/L比9.32±24.24 mg/L,P=0.175),术后30天hsCRP水平亦无显著差异(3.54±5.98 mg/L比2.63±4.32 mg/L,P=0.316)。结论冠心病患者介入治疗前hsCRP水平与术后1年内主要不良心血管事件的发生率存在正相关。冠心病患者围手术期的炎症反应在介入治疗30天后逐渐消退,这种变化可通过hs-CRP的浓度变化得到反映。     

Validating the Performance of 5 Risk Scores for Major Adverse Cardiac Events in Patients Who Achieved Complete Revascularization After Percutaneous Coronary Intervention

BackgroundRisk scores, like the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) score (SS), clinical SS, logistic SS (core model and extended model [LSS_extended]), Age, Creatinine, and Ejection Fraction (ACEF) score, and modified ACEF score, are predictive for major adverse cardiac events (MACE; including all-cause mortality, myocardial infarction [MI], and revascularization) in patients who have undergone percutaneous coronary intervention (PCI). However, few studies have validated the performance of these scores in complete revascularization (CR) patients. We aimed to compare the performance of previous risk scores in patients who achieved CR after PCI.MethodsAll patients (N = 10,724) who underwent PCI at Fuwai Hospital in 2013 were screened, and those who achieved CR after PCI were enrolled. Risk scores were calculated by experienced cardiologists blinded to the clinical outcomes. Discrimination of risk scores was assessed according to the area under the receiver operating characteristic curve (AUC).ResultsFifty-one percent (5375/10,724) of patients who underwent PCI achieved CR. At a mean follow-up of 2.4 years, the mortality, MI, revascularization, and MACE rates were 1.2%, 1.0%, 6.3%, and 7.7%, respectively. SS was not predictive for mortality (AUC, 0.51; 95% confidence interval [CI], 0.44-0.59). All scores involving clinical variables, especially modified ACEF score (AUC, 0.73; 95% CI, 0.66-0.79), could predict mortality. LSS_extended was the most accurate for MI (AUC, 0.68; 95% CI, 0.61-0.75). SS and LSS_extended were predictive for revascularization, with marginally significant AUCs (SS, 0.54; LSS_extended, 0.55). No score was particularly accurate for predicting MACE, with AUCs ranging from 0.51 (ACEF score) to 0.58 (LSS_extended).ConclusionsIn CR patients, risk scores involving clinical variables might help to predict mortality; however, no risk scores showed helpful discrimination for MACE.     

A Propensity Score Matched Analysis of Statin Effects on Major Adverse Cardiac Events after Percutaneous Coronary Intervention in Patients Over 75 Years Old

Objective In an extremely aging society, it is beneficial to reconsider the value of medical treatment for extremely elderly patients. We therefore focused on the efficacy of statin therapy in extremely elderly patients. This study investigated the efficacy of statins for secondary prevention in patients over 75 years old. Methods This prospective multicenter registry included 1,676 consecutive extremely elderly patients with coronary artery disease who underwent successful percutaneous coronary intervention (PCI). The patients were followed up clinically for up to three years or until the occurrence of major adverse cardiac events (MACEs), defined as a composite of all-cause death and non-fatal myocardial infarction. Using propensity score methodology to eliminate selection bias, in a 1:1 matching ratio, we selected 466 pairs of patients for the analysis. Results During the median follow-up period of 25 months, MACEs occurred in 176 patients. The Kaplan-Meier analysis showed that statin treatment correlated with a lower probability of initial MACE occurrences within 30 days compared with no statin treatment (log-rank test, p<0.001). According to a landmark analysis at day 30, statin treatment still showed consistent effectiveness for reducing MACE occurrence during the follow up period (p=0.04). A multivariable Cox hazard analysis showed that statin therapy significantly reduced MACE occurrence (hazard ratio 0.55 [0.40-0.75], p<0.001). In the stratification analysis, statin therapy was especially beneficial in patients without symptomatic heart failure. Conclusion Statins were effective in preventing MACEs in extremely elderly patients after PCI.     

Association of CYP2C19 Loss-of-Function Alleles with Major Adverse Cardiovascular Events of Clopidogrel in Stable Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention: Meta-analysis

Cardiovascular Drugs and Therapy - It was aimed to determine the aggregated risk of MACE (major adverse cardiovascular events) in stable CAD patients carrying CYP2C19 LoF alleles taking...